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Viruses transmitted by Aedes mosquitoes, such as dengue, Zika,
and chikungunya, have expanding ranges and seem unabated
by current vector control programs. Effective control of these
pathogens likely requires integrated approaches. We evaluated
dengue management options in an endemic setting that combine
novel vector control and vaccination using an agent-based model
for Yucata´n, Mexico, fit to 37 y of data. Our intervention models
are informed by targeted indoor residual spraying (TIRS) exper-
iments; trial outcomes and World Health Organization (WHO)
testing guidance for the only licensed dengue vaccine, CYD-TDV;
and preliminary results for in-development vaccines. We evalu-
ated several implementation options, including varying coverage
levels; staggered introductions; and a one-time, large-scale vac-
cination campaign. We found that CYD-TDV and TIRS interfere:
while the combination outperforms either alone, performance is
lower than estimated from their separate benefits. The conven-
tional model hypothesized for in-development vaccines, however,
performs synergistically with TIRS, amplifying effectiveness well
beyond their independent impacts. If the preliminary performance
by either of the in-development vaccines is upheld, a one-time,
large-scale campaign followed by routine vaccination alongside
aggressive new vector control could enable short-term elimina-
tion, with nearly all cases avoided for a decade despite continuous
dengue reintroductions. If elimination is impracticable due to
resource limitations, less ambitious implementations of this com-
bination still produce amplified, longer-lasting effectiveness over
single-approach interventions.
dengue | vector control | dengue vaccines | mathematical modeling
Dengue virus (DENV) is an Aedes mosquito-borne pathogenthat threatens nearly half the global population, with esti-
mated annual infections of 390 million people resulting in 96
million symptomatic cases (1–5). The expanding geographic
range of Aedes spp., rapid urbanization, lack of sustained effec-
tive vector control strategies, and increased human mobility have
primed the world for increased transmission of dengue and other
Aedes-borne diseases, including chikungunya, Zika, and yellow
fever (6–9).
The World Health Organization (WHO) considers mosquito
control a necessary component of dengue management (10), but
due to global trends in DENV transmission, the dengue preven-
tion community has generally acknowledged that vector control
is not sufficient for containment (6, 7, 11). Research and devel-
opment of vaccines have expanded to address this gap (12–19),
but the complex immune response to dengue has proven a major
challenge (20). DENV has four serotypes, and infection induces
long-lived immunity against the infecting serotype as well as
temporary immunity against the other serotypes. While initially
protective, this differential immune response can later increase
the risk of symptomatic and severe disease (21). To be effica-
cious, a vaccine needs to evoke broad, durable immunity while
avoiding this negative cross-reactive response.
Phase III trial results for a candidate vaccine, CYD-TDV
(commercially known as Dengvaxia), were initially promis-
ing, indicating that it was effective against all serotypes (12,
13). Follow-up studies, however, concluded that it had simi-
lar long-term immune outcomes to natural dengue infections:
temporary broad immunity followed by increased risk of dis-
ease for first natural infections (14, 22). Recipients with past
natural infections showed 68 to 90% efficacy depending on
serotype (23). The WHO now recommends only vaccinating
people with a laboratory-confirmed prior dengue infection (24,
25). Preliminary results of human challenge and immunogenic-
ity experiments for two other dengue vaccines developed by
NIH/Butantan/Merck and Takeda indicate tetravalent responses
in 90 to 100% (18, 19) and 60 to 100% (16, 17) of individuals,
respectively. Both vaccines are currently in phase III trials that
will soon produce additional results about efficacy.
Novel vector controls are also being developed. In addition
to more experimental approaches, like Wolbachia and gene
drives (11), insecticide-based methods with proven performance
against malaria are now being considered for Aedes aegypti.
Field experiments and mathematical modeling have shown that
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household-based targeted indoor residual spraying [TIRS; apply-
ing residual insecticides only to Ae. aegypti resting sites; e.g.,
exposed low walls (26, 27)] could be effective at preventing
dengue cases in endemic areas (28, 29). TIRS has also been
shown to be less expensive than classic indoor residual spraying
(IRS) while maintaining a high level of efficacy (30).
Unfortunately, both vaccination and vector control ap-
proaches have operational downsides. Without large-scale, one-
time campaigns in broad age groups (also known as “catch-up”
campaigns), forecast models suggest that routine vaccination
of narrow age groups with a conventional vaccine against
dengue would take decades to achieve high effectiveness (31).
Expanded vector control, on the other hand, initially shows
remarkable effectiveness but dynamically fades over time as nat-
urally acquired immunity in the population declines (29, 32).
The timing of these trends is complementary, and simple ordi-
nary differential equation models suggest that combining the
interventions might address their separate weaknesses (33).
While it is important to understand general trends, sim-
ple models may not provide sufficiently accurate quantitative
forecasts for real-world decision making. Based on prelimi-
nary estimates of intervention performance, we used our fitted
model of dengue transmission in the Mexican state of Yucata´n
to quantitatively assess different deployment strategies. While
future intervention decisions will need to be guided by empiri-
cal data not yet available, our results will be useful for narrowing
the potential programs for detailed consideration. This work
also demonstrates an intervention assessment framework, which
can be rapidly adjusted to account for updated intervention
performance.
We evaluated distinct mechanisms representing CYD-TDV
and an extrapolation of the ongoing phase III trials for the
NIH/Butantan/Merck and Takeda vaccines considering realis-
tic deployment options: 80% attempted coverage via routine
vaccination in children as well as adding a one-time catch-up
campaign at the same coverage. Quantitative findings vary sub-
stantially depending on the vaccine mechanism assumed. When
simulating the combination of CYD-TDV [given only to test-
seropositive 9-y-old children, consistent with current WHO rec-
ommendations (25)] and TIRS, the two interventions interfere
across a range of transmission settings; while their combination
generally outperforms either alone, the result is lower than what
might be na¨ıvely expected given their individual benefits. How-
ever, if either of the NIH/Butantan/Merck or Takeda vaccine
trials achieves the target efficacy outcomes—namely, demon-
strating a tetravalent, durable, highly efficacious vaccine—then
we predict that new vaccine will have an amplifying interac-
tion with TIRS, suggesting a promising integration of control
methods currently in development.
Results
Using an agent-based model of DENV transmission in the state
of Yucata´n, Mexico (Fig. 1), we forecast the impact of vacci-
nation and vector control interventions independently and in
combination. These interventions were introduced in a popu-
lation with stable dengue dynamics, and we simulated 40 y of
intervention to capture long-term trends.
To assess intervention performance, we focus on annual effec-
tiveness, which is the fraction of cases (i.e., symptomatic infec-
tions) prevented across the entire population, aggregated at
yearly intervals from the start of the intervention. The reduction
is measured against a baseline scenario without interventions.
We report cumulative effectiveness (i.e., the fraction of all
cases prevented since the start of the intervention) as well as
interquartile prediction intervals in SI Appendix.
Single-Intervention Scenarios. We updated our previous
single-intervention simulations (29, 31, 34) to reflect model
Fig. 1. Agent-based model structure. (Upper) Our model’s state transition
diagram for individual humans (E, Exposed; I, infectious [A, asymptomatic;
S, symptomatic; and W, withdrawn from daily activity]; R, recovered; and
S, susceptible) and mosquitoes (E, exposed; I, infectious; and S, susceptible).
Solid arrows denote possible transitions; dashed arrows denote the influ-
ence of infectious mosquitoes and humans on DENV transmission rates.
For humans, this series of transitions can occur for each serotype; each
mosquito may only be infected by a single serotype. (Lower) Overall model
spatial structure, zooming to Izamal (Insets) to illustrate detailed struc-
ture. Households, workplaces, and schools (Right Inset) are placed based
on government data and are consistent with satellite imagery (Left Inset);
SI Appendix, Fig. S1 shows enlarged versions of Insets. Pixel size in density
map is 430× 460 m.
improvements and to provide a consistent benchmark for com-
parison (Fig. 2). These updated results are broadly consistent
with those previously published. Here, we consider two vaccine
intervention models: 1) a conventional vaccine model with
tetravalent, durable efficacy against infection of 70% (hereafter
D70E, with hypothetical efficacy based on the results in refs.
16–19; see Fig. S13 for alternative efficacy values) and 2) a
natural infection-like model of CYD-TDV, which is initially per-
fectly efficacious but linearly wanes to zero efficacy over 2 y and
contributes to infection history, administered only to individuals
who test seropositive, with 20% false seronegative and 5% false
seropositive rates (SI Appendix, Figs. S8–S11 show effects of
alternative test performance assumptions). For both vaccine
models, we assume that the efficacy is the probability that each
exposure is resisted, also known as a “leaky” vaccine mechanism.
Materials and Methods has full vaccine model details.
At the population level, these distinct vaccine models initially
perform indistinguishably, but CYD-TDV performance drops
off after 2 y, coincident with waning protection at the individual
level. As expected for both vaccine models, a catch-up campaign
(i.e., a large-scale, one-time program covering individuals older
than routine recipients) increases the population-level effect, but
that effect wanes, either quickly with vaccine efficacy (CYD-
TDV model) or more slowly with demographic turnover (D70E
model), and performance eventually converges with conducting
routine-only vaccination. TIRS has high early effectiveness but
rapidly fades as naturally acquired population-level immunity
wanes (29).
Combination Interventions. We forecast performance of both vac-
cine mechanisms in combination with TIRS. One way to estimate
2 of 7 | www.pnas.org/cgi/doi/10.1073/pnas.1903496117 Hladish et al.
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Fig. 2. Simulated performance for single interventions. Overall annual
effectiveness for TIRS-only (Upper; blue) and vaccine-only interventions
(Lower; green). Results are aggregated annually, with some points enlarged
for readability. We generally use the visual distinctions introduced in this
figure throughout the manuscript.
population-level benefits of combined interventions is to assume
that interventions prevent the same proportion of cases whether
used separately or in combination. For example, if intervention
A prevents 50% of cases and intervention B prevents 60%, we
might estimate 20% [(1− 0.5)(1− 0.6)= 0.2] to remain. How-
ever, interventions at the population scale may interact, which
can be either amplifying (i.e., having greater effect than the
na¨ıve estimate) or interfering (i.e., having lesser effect). We
illustrate this for our scenarios in Fig. 3; Fig. 3, Upper shows
example independent interventions and corresponding na¨ıve
estimate benchmarks, and Fig. 3, Lower compares this bench-
mark with the actual simulated effectiveness. Because infectious
disease systems are generally nonlinear (including our model)
(SI Appendix, Fig. S7) and the individual interventions do not
approach elimination, we expect amplification.
As shown in Fig. 3, Lower, the most ambitious scenario—75%
TIRS coverage combined with routine D70E vaccination and a
one-time catch-up campaign—results in amplification that main-
tains population-level effectiveness above 95% for a decade.
Under these circumstances, DENV circulation is only main-
tained in our model by external introductions, suggesting that
elimination is plausible. In contrast, TIRS with CYD-TDV shows
short-term, modest amplification and long-term interference.
Fig. 4 shows similar trends for all of the vector control plus
vaccine coverage scenarios. All combinations exceeded the per-
formance of their individual components. In general, D70E has
amplifying interactions with TIRS, while CYD-TDV had inter-
fering ones. The interaction magnitude increases with increasing
TIRS coverage. Vaccination programs with a catch-up campaign
also increase the short-term interaction magnitude. This matches
intuition: as interventions are scaled up, they have the potential
to interact more strongly.
CYD-TDV only shows amplification during the 10 to 15 y after
a catch-up campaign. Catch-up vaccination candidates are older,
and thus, they are more likely to be seropositive and eligible for
the vaccine; after vaccination, this large group strictly benefits
from future TIRS. For routine vaccination, however, each new
cohort has reduced seroprevalence due to past TIRS and thus,
reduced eligibility. This CYD-TDV model would still benefit
seronegative recipients if they are ultimately likely to experience
two or more infections (34), and therefore, declining eligibility
reduces future benefits. This effect could be mediated by repeat
testing (35), but we did not explore that in this work.
Staggered Starts for D70E Combination Interventions. In some set-
tings, beginning two ambitious interventions at the same time
might be unrealistic, but a staggered introduction of the interven-
tions might be feasible (e.g., one intervention is possible now, but
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Fig. 4. Combined intervention effectiveness. D70E combined with TIRS ([Left] 25%, [Center] 50%, and [Right] 75% coverage) quickly results in dengue
control that equals or exceeds naı¨ve estimates. Because CYD-TDV eligibility depends on past natural infection, reducing DENV transmission with TIRS leads
to interference in our model.
the other is not ready to deploy, or both are available, but are too
costly to start concurrently). Because both aggressive TIRS and
routine D70E vaccination with a one-time catch-up campaign
are individually highly effective in the first few years, concur-
rent starts might have little advantage. We evaluated combined
interventions that do not begin at the same time (Fig. 5), instead
delaying the second intervention by 2, 5, or 8 y. We also consid-
ered a less aggressive catch-up campaign for D70E: instead of
all individuals older than age 2, we targeted only up to age 50
and spread the campaign over 2 y rather than completing it in
1 y. In all instances, we found that reducing the aggressiveness
of the catch-up campaign had minimal consequences, and within
2 y of adding the second intervention, annual effectiveness was
indistinguishable from starting interventions concurrently with
the more intense catch-up campaign. The impact on cumulative
effectiveness increased with the second intervention delay but
was above 80% after 20 y in all scenarios.
CYD-TDV Sensitivity to Mosquito Population Density. As shown pre-
viously (34), CYD-TDV vaccine effectiveness is sensitive to
transmission intensity in the target population. To extend these
results to combined interventions, we evaluated effectiveness
of this vaccine mechanism for different transmission levels by
varying mosquito population density (Fig. 6). CYD-TDV effec-
tiveness still follows mosquito density and thus, transmission
when serostatus testing is required. The interaction between
CYD-TDV and TIRS remains interfering at all densities that
we considered. At the lowest transmission level, however, this
effect is greatly diminished, likely because 75% TIRS in a
low-transmission setting causes individuals in the model to typ-
ically experience zero or one lifetime infection and thus, have
no need for CYD-TDV. Shifting from the as fitted to the
high-transmission setting, the long-term effectiveness of TIRS
decreases by roughly half, implying reduced effect on sero-
prevalence in routine vaccination candidates and shrinking the
interference deficit.
Discussion
Forecasts indicate that even ambitious vector control programs
or historically high levels of durable, efficacious vaccine cover-
age would fail to reduce DENV transmission below the endemic
threshold year round (29, 31, 34). Based on data for the state
of Yucata´n, DENV transmissibility is high enough that, given
regular reintroductions, the long-term burden is only reduced
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Fig. 6. CYD-TDV sensitivity to mosquito population density. As transmission increases, long-term performance of routine CYD-TDV combinations approaches
the naı¨ve estimate. Combinations consistently outperform either intervention alone, although only marginally outperforming TIRS in the lowest transmission
setting.
by about half by even the most ambitious single-intervention
strategies that we considered in our model. Reducing mosquito
populations reduces dengue incidence for several years, but after
population immunity declines as a result, even small numbers
of mosquitoes can effectively transmit DENV (36). Similarly,
for a leaky vaccine model, even the high coverage achieved by
long running programs cannot prevent repeated exposures from
producing cases. A higher force of infection, common in other
dengue-endemic settings, would drive this benefit lower.
However, these interventions complement each other, con-
tributing effectiveness when the other is lacking. Reasoning from
a simple dynamics perspective suggests that combining them may
yield consistent high effectiveness. We quantify this effect and
confirm that the intuition holds for D70E and TIRS using a
detailed model of DENV transmission in the state of Yucata´n,
Mexico. Our model clearly shows the advantages of integrat-
ing a new vector control intervention like TIRS in combination
with an efficacious vaccine: an ambitious control scenario—75%
TIRS coverage, 80% routine vaccination of 2-y-old children,
and a large-scale, one-time catch-up campaign vaccinating older
individuals—predicts a high, long-term impact: >83% reduc-
tion in cases every year for 40 y. Short-term effectiveness was
even better, with >96% effectiveness for the first decade and
>90% for the first 20 y. If ongoing phase III trials for new
dengue vaccines show efficacy comparable with or better than
the 70% that we assume, these results suggest that elimination
could be possible with a more expansive deployment of this strat-
egy as under these conditions, the model only sustains dengue
by occasional external reintroductions. Dengue control organi-
zations have long advocated for integrated interventions, and
this model can aid in allocating a finite budget to components
of an integrated program. The appropriate allocation would be
determined by more conclusive empirical evidence for interven-
tion efficacies as well as other logistical concerns. For example, a
sufficiently high-efficacy vaccine would lessen the need for exten-
sive new vector control for dengue, but vector control might
reduce the burden of other Aedes-borne diseases. Limited sup-
ply and high demand for a new, highly efficacious vaccine might
make additional vector control more practical than a one-time
mass vaccination campaign in order to achieve early effective-
ness, while a low-efficacy vaccine would suggest more emphasis
on vector control over a long time horizon (SI Appendix, Fig. S13
has alternative vaccine efficacy results).
Even without prioritizing elimination, understanding the ben-
efits of combining interventions may justify larger investments in
control programs. One might na¨ıvely assume that because vec-
tor control and vaccination are independent interventions with,
for example, individual effectiveness rates of 25 and 50% after
20 y, respectively, the combination would jointly prevent 62.5%
of cases. However, that treats the interventions as if they only
prevented symptoms and not infections (i.e., a linear effect)
and ignores reductions to onward transmission. For interven-
tions that reduce transmission, amplification may be possible:
infectious disease spread in general is exponential, saturating
as the system approaches infection of the entire susceptible
population. For a disease as transmissible as dengue, a sin-
gle intervention might not be enough to reduce cases much
below the saturating limit, while combined interventions could
still reduce transmission close to or in principle, below the epi-
demic threshold. We see these enhanced returns for D70E and
TIRS combinations: for the 25 and 50% effectiveness exam-
ple above, we actually forecast an 83% reduction rather than
62.5%. This amplifying interaction generally fails for CYD-TDV,
however, because the vaccine’s benefits vary with the rate of
past infection.
The interference that we predict between CYD-TDV and
TIRS should be expected for CYD-TDV combined with any
intervention that reduces the rate of natural infection. For
the scenarios that we considered, the CYD-TDV and TIRS
combination still outperformed either single approach, but the
modest benefit of combining interventions implies lower cost-
effectiveness per incremental investment compared with either
intervention alone. In some low-transmission scenarios that we
evaluated (SI Appendix), we observed actual net negatives, indi-
cating that adding CYD-TDV to TIRS could perform worse than
TIRS alone.
Beyond the interventions considered here, we would expect
control programs that are truly mechanistically independent to
show amplification when combined. If one of the interventions
depends on a dynamic process that the other prevents, however,
interference becomes possible.
Although there can be substantial benefits to combining inter-
ventions, simultaneously starting both could be logistically chal-
lenging in regions with a high dengue burden. Additionally,
although candidate vaccines with similar performance may be on
the horizon, D70E is still hypothetical, while TIRS (and other
novel vector control approaches) could be deployed relatively
soon. To address these potential challenges, we investigated
staggering the start dates of the two interventions. These more
gradual approaches to a combined intervention strategy are
promising: the lower initial annual effectiveness associated with
delaying either of the interventions recovers to the level of the
concurrent start within a year of adding the second intervention.
We also considered catch-up campaigns with a more restricted
demographic group in this analysis, which had no discernible
impact on intervention performance.
While the reasons for staggering campaigns might also suggest
stopping vector control after some period, we did not investigate
Hladish et al. PNAS Latest Articles | 5 of 7
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that option. Vector control might cease unintentionally due to
other circumstances (for example, civil unrest), but a deliber-
ate decision to cease vector control seems unlikely: vaccination
might be sufficient for dengue, but Aedes control reduces trans-
mission of multiple diseases. Furthermore, past results indicate
that ceasing vector control, whether intentional or incidental, can
lead to extreme outbreaks (29).
We also did not consider alternative timings for CYD-TDV
combinations as we found that effectiveness was consistently
below 40% after 15 y, regardless of whether it was coupled
with TIRS. The accepted model of CYD-TDV is essentially one
of protection against disease and only for vaccinees with some
level of prior dengue immunity (22, 24). Although interventions
involving CYD-TDV generally reduced the dengue disease bur-
den in our model, CYD-TDV is likely not compatible with a
strategy to eliminate or even substantially reduce dengue trans-
mission for more than a few years. As transmission decreased,
the vaccine became less useful, whether due to TIRS (in combi-
nation strategies) or CYD-TDV itself (in catch-up campaigns).
This outcome should be carefully considered in locations con-
templating using the CYD-TDV vaccine in combination with
new vector control efforts.
Building a combined intervention program by deploying its
components in different years is just one way to address logis-
tical constraints. More generally, deciding how best to allocate
finite resources among multiple interventions remains an open
question to be regularly revisited as new data become avail-
able and additional products enter the market. While single
interventions might, in principle, be able to achieve the pre-
dicted level of effectiveness of combined interventions, they
would require very high individual efficacy and coverage. Those
high-performance requirements are likely to be more difficult
to achieve than introducing a combined intervention built with
components that have good, but not astonishing, performance.
Combining interventions may also have impacts beyond what
we have explored here; for example, reduction of Aedes popu-
lations will have benefits with respect to other diseases spread by
the vector.
As our understanding of the mode of action, performance,
and costs of available interventions improves, the question of
which combinations are most effective will need to be revisited.
We show here, however, that interventions can be strongly syn-
ergistic, offering public health officials a more powerful control
strategy than might be na¨ıvely anticipated.
Materials and Methods
Using an agent-based model of dengue transmission in Yucata´n, Mexico,
we simulated the impact of a range of single and combined interventions;
SI Appendix has full details. The transmission model was fit to dengue case,
serotype, and seroprevalence data using AbcSmc (37) and then, run until
dengue dynamics were stable. Each intervention scenario was simulated
10,000 times (1,000 parameter combinations from the fitted posterior each
repeated with 10 different random seeds).
TIRS Vector Control Model. TIRS campaigns occur annually. During a 90-d
rollout period starting in late May (specifically Julian day 147, the opti-
mal date identified in ref. 29), 75% of houses, randomly drawn each year,
are treated with an insecticide that remains active for 90 d. Treatment
date for individual houses is chosen randomly within the rollout period. In
actively protected households, the insecticide causes 13% excess daily vector
mortality, which results in an 80% reduction in the hypothetical mosquito
population size at that location as well as shorter lifespans for infectious
mosquitoes.
Vaccine Models. We consider two vaccine efficacy models, which we refer to
as D70E (representing a performance estimate for the vaccines currently in
trials) and CYD-TDV (intended to explicitly model that vaccine).
The simple efficacy vaccine, D70E, is similar to but simpler than the
vaccine used in ref. 31: durable and 70% efficacious against all serotypes
conferred in a single dose. Vaccine performance is not affected by serosta-
tus of the recipient. When breakthrough infections occur, we assume that
the vaccine prevents 80.3% of severe cases, which instead manifest as nonse-
vere symptomatic cases (12). This vaccine model is plausible for some of the
vaccines that are in phase II and phase III trials (17, 38) and serves a work-
ing estimate until successful licensure of one or more of those products. We
also provide results for 50 and 90% efficacy vaccines for this mechanism in SI
Appendix, which can provide guidance on how intermediate efficacy values
that we did not simulate would perform.
The CYD-TDV model is based on the mechanism identified by ref. 22
as providing the best explanation of the CYD-TDV trial data and is the
same model used by the UF modeling group in ref. 34. CYD-TDV is mod-
eled as a three-dose vaccine delivered at 6-mo intervals only administered
to individuals who test seropositive. The vaccine mechanism includes three
effects: 1) immunity against infection (supported by ref. 39) that wanes
linearly following each dose, from perfect to nothing over 2 y, resulting
in a complete loss of immunity against infection after 3 y from the ini-
tial dose; 2) initial immunity against severe disease of 80.3% in the case
of breakthrough infections, which also wanes linearly to nothing over 2
y from the most recent dose; and 3) the vaccine increments infection his-
tory like a natural infection, meaning that individuals who falsely test
seropositive are at enhanced disease risk on their first natural infection.
Seropositive recipients thus unambiguously benefit from the vaccine, if
only temporarily, while seronegative recipients eventually have an increased
risk of disease from their next natural infection. Consistent with current
WHO guidance (25), the vaccine is only administered to seropositive indi-
viduals, which we determine using a serological test. In the results, we
assume a test with 5% false seropositive rate and 20% false seronegative
rate; SI Appendix has additional details and consequences of alternate test
characteristics.
Vaccination with either mechanism probabilistically prevents infections
when an exposure occurs based on the vaccines efficacy at that time. Over
each simulated day, infectious mosquitoes may bite individuals who are
at the same locations (i.e., house, workplace, or school). Those individuals
who do not have naturally acquired immunity (i.e., no previous infection
with the exposure serotype and no infection with any serotype within
the last 2 y) are considered exposed due to such bites. If exposed indi-
viduals have received a vaccine, they can resist infection with probability
equal to the vaccine efficacy. For durable vaccines, efficacy is constant; for
waning vaccines, efficacy depends on the time since the individual was
vaccinated. For both models, every exposure is an independent chance
to break through the vaccine protection (i.e., the vaccine efficacy model
is leaky).
The two vaccine models have different target age eligibility. For CYD-
TDV, we consider routine-only vaccination of 9-y-old children and one-time
catch-up campaigns for 10- to 50-y-old individuals. Because CYD-TDV is
only recommended for use in seropositive candidates, the size of the eli-
gible population is affected by recent dengue epidemics. In our fitted
model population, seroprevalence of 9-y-old children has a median of 56%
(interquartile range: [51, 63%]) across replicates at steady state (SI Appendix
has additional characterization of the synthetic population). After inter-
ventions are introduced, dengue incidence generally decreases, and thus,
so does seroprevalence among 9-y-old children, decreasing the eligible
population for CYD-TDV.
For D70E, for all but the staggered start date combinations shown in
Fig. 5, we consider routine-only vaccination of 2-y-old children and one-
time catch-up campaigns for 3 y and older. For the results in Fig. 5, we limit
the D70E catch-up campaign to 3- to 50-y-old individuals spread over 2 y.
For both vaccine models and both routine administration and the one-time
catch-up campaign, we consider 80% of the target group for vaccine cover-
age. Since CYD-TDV is only administered to test-seropositive individuals, the
realized coverage may be lower.
Effectiveness and Interaction Calculations. We calculate effectiveness
(annually or cumulatively) for a single or combination intervention
strategy as
effX = 1−
cases with intervention X
cases without intervention
.
The effectiveness difference between simulated and estimated com-
bined interventions of a vaccination strategy V and a mosquito control
strategy M is
Φ = effV+M − (effV + effM − effVeffM).
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To calculate these values, we match baseline and intervention runs
by parameter combination and report medians in the text; interquartile
prediction intervals are in SI Appendix.
Data Availability
All code necessary to reproduce the simulation results is
available from GitHub, https://github.com/tjhladish/dengue. SI
Appendix documents the detailed data sources. IPUMS-
International microcensus data may be obtained by request from
https://international.ipums.org/international/; all other data are
publicly available from the sources indicated.
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